From Blockbuster to Nichebuster

Questions: Discounts, Updates etc.

Price: $1,425.00

Publication Date: 2006-07-24

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

For 25 years, blockbusters have played a key role in driving strong drug market growth. However, pressure on blockbusters is increasing, as both regulators and payers are shifting away from me-too drugs, which in the past have been fertile ground for blockbusters. Furthermore, blockbusters attract significant generic competition and may also stifle R&D innovation.


Scope

  • Overview of the role that blockbusters have played in shaping and driving market growth
  • Identification of which niche disease markets to target, to maximize value from the nichebuster model
  • Examination of how a range of different drivers such as regulatory initiatives are incentivizing the nichebuster model
  • Identification of trends underlying R&D collaborations or licensing deal activity in allowing Big Pharma to access novel technologies and markets


    • Report Highlights
    To successfully capitalize on the nichebuster model, drugs companies should focus on characterizing the target market, and use targeted marketing spend to access specialist physicians to drive clinical trial progression, approval and successful uptake

    Dependence on blockbuster-generated revenue is set to fall from 2004-2010 as the industry turns to a nichebuster strategy, utilizing increased licensing activity, R&D collaborations and small-scale M&A deals to harness innovation and provide access to niche markets with a high unmet need

    The shift into niche markets is helping drive a more personalized approach to therapy. Central to the development of the nichebuster model is the raised importance of personalized therapies, which is being driven by increased used of diagnostics. This trend is helping to clarify market segmentation and will boost the size of the total drug industry


    Reasons to Purchase

  • Identify why blockbusters have played such an important role in pharma/biotech market development
  • Understand why it is no longer optimal for this strategy to play a central role in driving future growth
  • Gain insight into how the transition towards the nichebuster model will change overall market dynamics in the future

    • Table of Contents

    Other users found this report page using the following search terms: blockbuster nichebuster nichebuster blockbuster pharma strategy niche blockbusters market target areas productivity

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.